Khiron speculative buy recommendation reaffirmed
CanaccordGenuity has updated its research report on Khiron Life Sciences (TSX: KHRN). From a price of $1.30 per share that equates to a market cap of $110 million, the target price of $3.40 per share and speculative buy recommendation is reaffirmed.
Kimberly Hedlin, CPA, CMA, author of the report says, “Given the recent focus on the LATAM cannabis sector, we are reiterating our C$3.40 target and SPEC BUY rating on Khiron.” In other words, Canaccord suggests that KHRN should not be tarred with the same brush as APHA and other targets of the Hindenburg/Quintessential Capital Management (H/QCM) report.
I agree with Canaccord’s findings as it basically supports my recent report on Seeking Alpha, “Kihron Life Sciences is the Real Deal.”